Initiation of ART: Choosing a First Regimen

Module 7, Version 4

References

  • Clotet B, Feinberg J, van Lunzen J, et al. and the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naïve adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase IIIb study. Lancet. 2014;383:2222-2231.
  • Cohen CJ, Molina JM, Cahn P, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: Pooled results from the phase III double-blind randomized ECHO and THRIVE Trials. J Acquir Immune Defic Syndr. 2012;60:33-42.
  • Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
  • Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375:830-839.
  • Deeks SG. HIV Infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2011;62:141-155.
  • Elion RA, Althoff KN, Zhang J, et al. Recent abacavir use increases risk of type 1 and type 2 myocardial infarctions among adults with HIV. J Acquir Immune Defic Syndr. 2018 May 1;78(1):62-72.
  • Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: A randomised, double-blind, active-controlled phase III trial. Lancet HIV. 2016;3:e158-e165.
  • Hoffman C, Weiz T, Sabranski M, et al.  Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med.  2017. Jan;18(1):56-63.
  • INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373:795-807.
  • Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet. 2009;374:796-806.
  • Lennox JL, Landovitz RJ, Ribaudo HJ, et al. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naïve volunteers infected with HIV-1: A randomized, controlled equivalence trial. Ann Intern Med. 2014;161:461-471.
  • McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-801.
  • Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study. Lancet HIV. 2016 Jan;3:e23-e32.
  • Mugavero MJ, Napravnik S, Cole SR, et al. Viremia copy-years predicts mortality among treatment-naïve HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis. 2011;53:927-935.
  • Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. AIDS. 2008;22:1389-1397
  • Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naïve, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49-55.
  • Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase III study. J Acquir Immune Defic Syndr. 2016;71:530-537.
  • Raffi F, Jaeger H, Quiros-Roldan E, et al. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naïve adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis. 2013;13:927-935.
  • Rockstroh J, DeJesus E, Henry K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: Analysis of week 96 results. J Acquir Immune Defic Syndr. 2013;62:483-486.
  • Rockstroh JK, DeJesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: Final 5-year results from STARTMRK. J Acquir Immune Defic Syndr. 2013;63:77-85.
  • Sabin C, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir and myocardial infarction risk? BMC Med. 2016;14:6.
  • Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320(4):379-396.
  • Sax P, Tierney C, Collier A, et al. Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N Eng l J Med. 2009;361:2230-2240.
  • Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547-1556.
  • The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373:808-822.
  • Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807-1818.
  • Worm S, Sabin C, Weber R, et al. DAD Study Group. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from 3 major drug classes. J Infect Dis. 2010;201:318-330.
  • Young J, Xiao Y, Moodier EE, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2015;69:413-421.
  • Zolopa A, Sax P, DeJesus E, et al. A randomized double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus favirenz/emtricitabine/tenofovirdisoproxil fumarate for initial treatment of HIV-1 infection: Analysis of Week 96 results. J Acquir Immune Defic Syndr. 2013;63:96-100.
  • Cahn P, Kaplan R, Sax P, et al. Raltegravir (RAL) 1200 mg once daily (QD) is non-inferior to RAL 400 mg twice daily (BID), in combination with tenofovir/emtricitabine, in treatment-naïve HIV-1-infected subjects: Week 48 results. 21st International AIDS Conference (AIDS 2016). Durban, July 18-22. Abstract FRAB0103LB.
  • Cohen MS, et al. Final results of the HPTN 052 randomized controlled trial: Antiretroviral therapy prevents HIV transmission. Program and abstracts of the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention; July 19-22, 2015; Vancouver, Canada. Abstract MOAC0101LB.
  • Quercia R, Roberts J, Hoffmann C, et al. Psychiatric adverse events from the DTG ART-naïve phase 3 clinical trials. HIV Drug Therapy 2016. Glasgow, October 23-26, 2016. Abstract P210.
  • Squires K, Kityo C, Hodder S, et al. Elvitegravir (EVG) / cobicistat (COBI) / emtricitabine (FTC) / tenofovir disoproxil fumarate (TDF) is superior to ritonavir (RTV) boosted atazanavir (ATV) plus FTC/TDF in treatment naïve women with HIV-1 infection (WAVES Study). 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Vancouver, July 19-22, 2015. Abstract MOLBPE0.

Thank you for visiting the AAHIVM Provider Education Center! 

In order to continue, we will need you to create a site profile. This will help us keep track of your education activity and CME accreditations. Please note, this profile will be different than your aahivm.org profile affiliated with AAHIVM membership or credentialing.

           NEW USERS CLICK HERE TO CREATE A SITE PROFILE.           

ALREADY CREATED YOUR SITE PROFILE? CLICK HERE TO SIGN IN.

Are you an AAHIVM member? If not, consider supporting the Academy and programs like these. Click here to become an Academy member.

 

Connect

Phone: 202-659-0699
Fax: 202-659-0976

Contact

AAHIVM National Office
1705 DeSales Street NW, Suite 700
Washington, D.C. 20036

About

The American Academy of HIV Medicine is a professional organization that supports the HIV practitioner and promotes accessible, quality care for all Americans living with HIV disease. Our membership of HIV practitioners and credentialed HIV Specialists™, HIV Experts™, and HIV Pharmacists™ provide direct care to the majority of HIV patients in the US.